



## **ALX Oncology Announces Trials in Progress Abstracts Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting**

October 5, 2022

SOUTH SAN FRANCISCO, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the acceptance of two Trials in Progress abstracts related to ASPEN-03 and ASPEN-04, the Company's Phase 2 head and neck cancer studies in collaboration with Merck (known as MSD outside the US and Canada), at the SITC 37<sup>th</sup> Annual Meeting in Boston, MA, from November 8–12, 2022.

### **Poster Presentation Details**

**Title:** A phase 2 study of evorpaccept (ALX148) in combination with pembrolizumab in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-03

**Abstract Number:** 678

**Session Date and Time:** November 10-11, 2022, from 9:00 am – 9:00 pm ET

**Location:** Poster Hall

**Title:** A phase 2 study of evorpaccept (ALX148) in combination with pembrolizumab and chemotherapy in patients with advanced head and neck squamous cell carcinoma (HNSCC); ASPEN-04

**Abstract Number:** 676

**Session Date and Time:** November 10-11, 2022, from 9:00 am – 9:00 pm ET

**Location:** Poster Hall

### **About ALX Oncology**

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, evorpaccept, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. Evorpaccept has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of evorpaccept for the treatment of multiple solid tumor indications and hematologic malignancies.

Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 [peter@alxoncology.com](mailto:peter@alxoncology.com) Argot Partners (212)-600-1902 [alxoncology@argotpartners.com](mailto:alxoncology@argotpartners.com) Media Contact: Karen Sharma MacDougall (781) 235-3060 [alx@macdougall.bio](mailto:alx@macdougall.bio)